Prothena Corporation (PRTA) Aktie Kurs

Prothena Corporation Kurs

NASDAQ·LUKKET
8,16
​
Markedet lukket

Omsætningen er vokset med 8,8 % om året de seneste 16 år til 9,68 Mio. USD. Prothena Corporations nettoavance ligger på -2.520,6 %, ned fra 33,4 % for flere år siden. Analytikernes mediankursmål er 24,50 USD, hvilket er over den aktuelle kurs med 200,2 %. Af 12 analytikere anbefaler 8 køb — den samlede vurdering er Køb.

Prothena Corporation aktiekurs

Hent disse data via Eulerpool API

100.000 requests/md. gratis · intet kreditkort

Prothena Corporation aktie og aktieanalyse

Prothena Corporation PLC er et biopharmaceutisk selskab baseret i Dublin, Irland, der specialiserer sig i udviklingen af terapier til proteinerelaterede sygdomme. Selskabet blev udskilt fra Elan Corporations forskningsafdeling i 2012 og har været noteret på NASDAQ siden 2014. Prothenas forretningsmodel er baseret på opdagelsen og udviklingen af nye terapeutiske tilgange til neurodegenerative sygdomme og kræft forårsaget af fejlfoldefte proteiner. Virksomheden udnytter sin ekspertise inden for proteinbio kemi og fysik til at identificere målrettede drug-kandidater, der kan modulere specifikke proteinstrukturer og deres funktioner. Prothenas hovedfokusområder inkluderer forskning i antistoffer mod amyloid-beta-plakker, der ophober sig i hjernen ved Alzheimers sygdom, samt udvikling af molekyler, der kan hæmme det sygdomsfremkaldende protein alpha-synuclein hos Parkinson-patienter. Derudover arbejder virksomheden på terapier til ATTR-amyloidosе og AL-amyloidosе. Et stort gennembrud for Prothena var udviklingen af NEOD001, et humaniseret antistof, der retter sig mod amyloidfibrilproteinet (AL), der deponeres ved AL-amyloidosе. Lægemidlet viste betydelig effektivitet i kliniske forsøg og forbedrede patienternes livskvalitet. Prothena licenserede NEOD001 til Pfizer i 2017. Et andet vigtigt produkt fra Prothena er PRX002, et monoklonalt antistof, der specifikt retter sig mod alpha-synuclein-proteinet og hæmmer dets spredning i hjernen. PRX002 gennemgår i øjeblikket kliniske forsøg til behandling af Parkinson-patienter og betragtes som et lovende lægemiddel. Prothena samarbejder tæt med forskningspartnere og andre farmaceutiske virksomheder såsom Roche/Genentech og Celgene for at fremme deres forskningsaktiviteter og udviklingen af nye terapier. Virksomheden har stærk reguleringserfarenhed og sigter efter at opnå godkendelser af nye terapier for at forbedre livskvaliteten for patienter med sjældne eller alvorlige sygdomme. Samlet set er Prothena en førende virksomhed inden for feltet proteinbio kemi og udviklingen af innovative terapier til proteinerelaterede sygdomme. Med et stærkt forskningspipeline og et bredt udvalg af produktkandidater har virksomheden potentiale til at forbedre livet for millioner af mennesker, der lider af alvorlige sygdomme.

Hyppigt stillede spørgsmål om Prothena Corporation-aktien

The business model of Prothena Corporation PLC revolves around the development and commercialization of novel therapies for the treatment of progressive diseases. Prothena focuses on the discovery and development of protein immunotherapies, specifically targeting misfolded proteins that are implicated in various neurodegenerative diseases. Through its innovative approach, Prothena aims to address unmet medical needs and improve patient outcomes. By leveraging its expertise in protein engineering, it strives to create transformative therapies that have the potential to significantly impact the lives of patients. Prothena Corporation PLC is committed to advancing its pipeline and partnering with strategic collaborators to further accelerate the development and commercialization of its innovative therapies.

Prothena Corporation PLC is primarily active in the biotechnology and pharmaceutical industries.

Some of the main competitors of Prothena Corporation PLC in the market include Biogen Inc., Ionis Pharmaceuticals Inc., and Alexion Pharmaceuticals Inc.

Prothena Corporation PLC is a biotechnology company specializing in the discovery and development of novel therapies for neurodegenerative diseases. Established in 2012, Prothena originated as a spin-off from Elan Corporation, focusing primarily on antibody-based therapies. The company's research and development efforts are centered around misfolded proteins implicated in diseases like amyloidosis, Parkinson's, and Alzheimer's. With a commitment to scientific innovation, Prothena utilizes its expertise in protein engineering to create transformative treatments. By leveraging its strong pipeline and collaborations, Prothena aims to provide hope to patients suffering from debilitating disorders and improve their quality of life.

Prothena Corporation PLC has achieved several significant milestones. The company successfully generated positive results in its Phase 1 clinical trials for PRX002/RG7935, a potential treatment for Parkinson's disease. Furthermore, Prothena entered into a worldwide collaboration with Roche to develop and commercialize PRX002/RG7935, receiving an upfront payment and potential milestone payments. Additionally, Prothena advanced its pipeline with the initiation of Phase 1 clinical trials for PRX004, a potential therapy for ATTR amyloidosis. These milestones demonstrate Prothena Corporation PLC's progress in developing innovative treatments and forging key collaborations in the field of neurodegenerative diseases.

Prothena Corporation PLC is primarily present in the United States and Europe. As a multinational biotechnology company, Prothena focuses on the discovery, development, and commercialization of immunotherapies for the treatment of neurodegenerative diseases. With its headquarters in Ireland, Prothena maintains a strong presence in major cities across the United States, including South San Francisco and Cambridge. Additionally, the company has operations in several European countries, such as Switzerland and the United Kingdom. Prothena's global reach enables it to collaborate with renowned academic institutions, healthcare providers, and research organizations to advance innovative therapies for patients worldwide.

Prothena Corporation PLC is a biotechnology company that focuses on developing transformative therapies for patients with neurodegenerative diseases. The company's values revolve around scientific innovation, integrity, collaboration, and patient-centricity. Prothena is committed to advancing the understanding of disease pathways and developing novel treatments that address unmet medical needs. With a mission to improve patient outcomes, Prothena prioritizes rigorous research, strategic partnerships, and efficient development processes. By combining cutting-edge science, a strong corporate philosophy, and a dedicated team, Prothena Corporation PLC strives to bring hope and potential breakthroughs to individuals affected by debilitating neurodegenerative conditions.

Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 24,50 USD for Prothena Corporation-aktien (median: 24,50 USD), svarende til +200,2 % i forhold til seneste kurs. Konsensus bygger på 12 analytikervurderinger.

12 analytikere vurderer i øjeblikket Prothena Corporation-aktien: 8 anbefaler køb, 3 hold og 1 salg. For 2026 forventer analytikere, at Prothena Corporation genererer omsætning på 72,42 Mio. USD og indtjening pr. aktie på -0,02 USD.

Omregnet til den aktuelle valutakurs handles Prothena Corporation-aktien til 7,40 EUR (8,16 USD).

Prothena Corporation-aktien (PRTA) er noteret på 5 børser, herunder: NASDAQ (PRTA), London (0Y3M.L), Frankfurt (0PT.F), München (0PT.MU), Düsseldorf (0PT.DU).

Prothena Corporation PLC is a leading biotechnology company specializing in the development of therapies for neurodegenerative diseases. The company, founded in 2012, is headquartered in Dublin, Ireland, and its main focus is on developing drugs against amyloid deposition in brain cells. The company's research and development division is the core of the company, where drugs targeting amyloid deposition in brain cells are developed. Prothena's production department guarantees that the drugs are produced in the highest quality and comply with strict regulatory requirements. Once a drug is approved by the FDA or EMA, Prothena markets and sells it. Prothena has developed NEOD001, a drug in clinical phase III, targeting patients with secondary systemic amyloidosis. The company also has other drugs in the pipeline focusing on Alzheimer's, Parkinson's, and ALS. Overall, Prothena is an innovative biotechnology company that makes a significant contribution to research on neurodegenerative diseases. Its focus on identifying specific antibodies against amyloid deposits in the brain is a promising approach with the potential to improve the lives of millions of people.

forventet-omsætningen for Prothena Corporation er 72,42 Mio. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

forventet-overskuddet for Prothena Corporation er -1,31 Mio. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Prothena Corporation er i øjeblikket -336,01. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Prothena Corporation-aktien.

Pris-til-salgs-forholdet (P/S) for Prothena Corporation er i øjeblikket 6,07. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Prothena Corporation-aktien.

AlleAktien-kvalitetsscore for Prothena Corporation er 4/10.

ISIN for Prothena Corporation er IE00B91XRN20. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Prothena Corporation er A1KAVV. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Prothena Corporation er PRTA. Tickersymbolet bruges til at handle Prothena Corporation-aktier på børsen.

Fair værdiTerminal
7,10 USD
Over-/underværdieringTerminal
Fair værdieret
Sektor
Industri
Bioteknologi
Antal aktier
Medarbeidere
Omsætning pr. medarbejder
144.537,31 USD
Omsætningsvækst Ø5 år
EBIT-vækst Ø5 år
Resultatvækst Ø5 år
Hjemmeside prothena.com
Land
Irland
Valuta
USD
Børsintroduktion
21. dec. 2012
ISIN
IE00B91XRN20
CUSIP
G72800108
SEDOL
B91XRN2
Markedsværdi
52-ugers interval
AAQS
4 / 10
PEG-forhold
—
P/E-forhold
P/Ee 2026
-336,01
P/Ee 2027
-8,03
P/Ee 2028
-33,17
P/Ee 2029
-16,93
P/Ee 2030
4,98
P/Se
6,07
EV/EBIT
0,95
K/B-forhold
1,57
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-87,03 %
Sidst opdateret 16. nov. 2026, 08.39

Prothena Corporation Peer Group

Prothena Corporation Ticker

DÜSSELDORF · 0PT.DUFRANKFURT · 0PT.FLONDON · 0Y3M.LMÜNCHEN · 0PT.MUNASDAQ · PRTA

Prothena Corporation FIGI

PRTA:US · BBG003PDKJF7PRTA:UA · BBG003PMQJ89PRTA:UC · BBG003PMQJ98PRTA:UN · BBG003PMQJC4PRTA:UP · BBG003PMQJD3PRTA:UB · BBG003PMQJG0PRTA:UM · BBG003PMQJJ7PRTA:UX · BBG003PMQJK5PRTA:UD · BBG003PMQJR8PRTA:UW · BBG003PMQJT6PRTA:UF · BBG003PMQJV3PRTA:VY · BBG003PMQJW2